“In the Brainport region we are very proficient at developing new ideas for regenerative medicine, but the path to the patient is long and challenging,” says Jan Rietsema, CEO of SBMC.

“Our aim is to accelerate the process from patent to patient. This is good for the patient and good for the dozens of start-ups in Southeast Brabant, such as Xeltis, STENTiT, and VivArt-X, companies spearheading the development of biomaterials for regenerative medical applications. Companies from in- and outside the consortium are welcome to get active in our shared facilities and use our expertise to further address their scaling and production
challenges.”

Otto van den Boogaard, CEO of High Tech Campus Eindhoven, adds, “We are delighted with
SBMC’s choice of the Campus. This decision not only confirms our position as a leading global healthcare hub but also highlights our vital role in supporting thriving innovation clusters. Through our top-notch facilities, we empower these dynamic groups to thrive, fostering groundbreaking advancements in healthcare and technology.”